12 participants
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-08-11
- Start Date:
- 2018-07-10
- Completion:
- 2020-12-10
Conditions
- Stage III Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Estrogen Receptor-positive
- HER2/Neu Negative
Interventions
- DRUG